[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021; 71, 209−49. doi:  10.3322/caac.21660
[2] Liu WP, Liu JM, Song YQ, et al. Burden of lymphoma in China, 2006-2016: an analysis of the global burden of disease study 2016. J Hematol Oncol, 2019; 12, 115. doi:  10.1186/s13045-019-0785-7
[3] Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood, 2006; 107, 265−76. doi:  10.1182/blood-2005-06-2508
[4] Sehn LH, Scott DW, Chhanabhai M, et al. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol, 2011; 29, 1452−7. doi:  10.1200/JCO.2010.33.3419
[5] Li SY, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology, 2018; 50, 74−87.
[6] Chen-Liang TH, Martin-Santos T, Jerez A, et al. The role of bone marrow biopsy and FDG-PET/CT in identifying bone marrow infiltration in the initial diagnosis of high grade non-Hodgkin B-cell lymphoma and Hodgkin lymphoma. Accuracy in a multicenter series of 372 patients. Am J Hematol, 2015; 90, 686−90. doi:  10.1002/ajh.24044
[7] Chen YM, Zhou MG, Liu JJ, et al. Prognostic value of bone marrow FDG uptake pattern of PET/CT in newly diagnosed diffuse large B-cell lymphoma. J Cancer, 2018; 9, 1231−8. doi:  10.7150/jca.23714
[8] Kaya Z, Akdemir OU, Atay OL, et al. Utility of 18-fluorodeoxyglucose positron emission tomography in children with relapsed/refractory leukemia. Pediatr Hematol Oncol, 2018; 35, 393−406. doi:  10.1080/08880018.2018.1557306
[9] Adams HJA, Nievelstein RAJ, Kwee TC. Opportunities and limitations of bone marrow biopsy and bone marrow FDG-PET in lymphoma. Blood Rev, 2015; 29, 417−25. doi:  10.1016/j.blre.2015.06.003
[10] El-Galaly TC, d'Amore F, Mylam KJ, et al. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. J Clin Oncol, 2012; 30, 4508−14. doi:  10.1200/JCO.2012.42.4036
[11] Vitolo U, Seymour JF, Martelli M, et al. Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2016; 27, v91−102. doi:  10.1093/annonc/mdw175
[12] Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol, 2014; 32, 3059−68. doi:  10.1200/JCO.2013.54.8800
[13] Cottereau AS, Meignan M, Nioche C, et al. Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT. Ann Oncol, 2021; 32, 404−11. doi:  10.1016/j.annonc.2020.11.019
[14] Kurch L, Hüttmann A, Georgi TW, et al. Interim PET in diffuse large B-cell lymphoma. J Nucl Med, 2021; 62, 1068−74. doi:  10.2967/jnumed.120.255034
[15] Freeman CL, Savage KJ, Villa DR, et al. Long-term results of PET-guided radiation in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP. Blood, 2021; 137, 929−38. doi:  10.1182/blood.2020005846
[16] Zhang XH, Chen L, Jiang H, et al. A novel analytic approach for outcome prediction in diffuse large B-cell lymphoma by [18F]FDG PET/CT. Eur J Nucl Med Mol Imaging, 2022; 49, 1298−310. doi:  10.1007/s00259-021-05572-0
[17] Burggraaff CN, Eertink JJ, Lugtenburg PJ, et al. 18F-FDG PET improves baseline clinical predictors of response in diffuse large B-cell lymphoma: the HOVON-84 study. J Nucl Med, 2022; 63, 1001−7. doi:  10.2967/jnumed.121.262205
[18] Adams HJA, Kwee TC, De Keizer B, et al. FDG PET/CT for the detection of bone marrow involvement in diffuse large B-cell lymphoma: systematic review and meta-analysis. Eur J Nucl Med Mol Imaging, 2014; 41, 565−74. doi:  10.1007/s00259-013-2623-4
[19] Aguado-Vázquez TM, Olivas-Martínez A, Cancino-Ramos U, et al. 18f-fluorodeoxyglucose positron emission tomography versus bone marrow biopsy for the evaluation of bone marrow infiltration in newly diagnosed lymphoma patients. Rev Invest Clin, 2020; 73.
[20] Teagle AR, Barton H, Charles-Edwards E, et al. Use of FDG PET/CT in identification of bone marrow involvement in diffuse large B cell lymphoma and follicular lymphoma: comparison with iliac crest bone marrow biopsy. Acta Radiol, 2017; 58, 1476−84. doi:  10.1177/0284185117701305
[21] Zaucha JM, Chauvie S, Zaucha R, et al. The role of PET/CT in the modern treatment of Hodgkin lymphoma. Cancer Treat Rev, 2019; 77, 44−56. doi:  10.1016/j.ctrv.2019.06.002
[22] El Karak F, Bou-Orm IR, Ghosn M, et al. PET/CT scanner and bone marrow biopsy in detection of bone marrow involvement in diffuse large B-cell lymphoma. PLoS One, 2017; 12, e0170299. doi:  10.1371/journal.pone.0170299
[23] Ujjani CS, Hill EM, Wang HK, et al. 18F-FDG PET-CT and trephine biopsy assessment of bone marrow involvement in lymphoma. Br J Haematol, 2016; 174, 410−6. doi:  10.1111/bjh.14071
[24] Moulin-Romsee G, Hindié E, Cuenca X, et al. 18F-FDG PET/CT bone/bone marrow findings in Hodgkin's lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging. Eur J Nucl Med Mol Imaging, 2010; 37, 1095−105. doi:  10.1007/s00259-009-1377-5
[25] Lakhwani S, Cabello-García D, Allende-Riera A, et al. Bone marrow trephine biopsy in Hodgkin's lymphoma. Comparison with PET-CT scan in 65 patients. Med Clín, 2018; 150, 104−6.
[26] Kaddu-Mulindwa D, Altmann B, Held G, et al. FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials. Eur J Nucl Med Mol Imaging, 2021; 48, 3550−9. doi:  10.1007/s00259-021-05348-6
[27] Schaefer NG, Strobel K, Taverna C, et al. Bone involvement in patients with lymphoma: the role of FDG-PET/CT. Eur J Nucl Med Mol Imaging, 2007; 34, 60−7. doi:  10.1007/s00259-006-0238-8
[28] Pelosi E, Penna D, Douroukas A, et al. Bone marrow disease detection with FDG-PET/CT and bone marrow biopsy during the staging of malignant lymphoma: results from a large multicentre study. Q J Nucl Med Mol Imaging, 2011; 55, 469−75.
[29] Cerci JJ, Györke T, Fanti S, et al. Combined PET and biopsy evidence of marrow involvement improves prognostic prediction in diffuse large B-cell lymphoma. J Nucl Med, 2014; 55, 1591−1597. doi:  10.2967/jnumed.113.134486
[30] Shagera QA, Cheon GJ, Koh Y, et al. Prognostic value of metabolic tumour volume on baseline 18F-FDG PET/CT in addition to NCCN-IPI in patients with diffuse large B-cell lymphoma: further stratification of the group with a high-risk NCCN-IPI. Eur J Nucl Med Mol Imaging, 2019; 46, 1417−27. doi:  10.1007/s00259-019-04309-4
[31] Cottereau AS, Nioche C, Dirand AS, et al. 18F-FDG PET dissemination features in diffuse large B-cell lymphoma are predictive of outcome. J Nucl Med, 2020; 61, 40−5. doi:  10.2967/jnumed.119.229450
[32] Islam P, Goldstein J, Flowers CR. PET-derived tumor metrics predict DLBCL response and progression-free survival. Leuk Lymphoma, 2019; 60, 1965−71. doi:  10.1080/10428194.2018.1562181
[33] Araz M, Soydal C, Ozturk C, et al. An uncommon presentation of diffuse large B cell lymphoma with multiple peripheral nerve involvement demonstrated BY 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging, 2020; 47, 218−9. doi:  10.1007/s00259-019-04428-y
[34] Lee JW, Oh D, Eom KY, et al. The prognostic value of PET/CT evaluation with Deauville score on the recurrence and survival in diffuse large B-cell lymphoma: a multi-institutional study of KROG 17-02. Clin Exp Metastasis, 2020; 37, 125−31. doi:  10.1007/s10585-019-09992-z